Initial NSAID monotherapy for polyarthritis in juvenile idiopathic arthritis (JIA) has been rejected in the most recent 2019 American College of Rheumatology / Arthritis Foundation guidelines. The guidelines differ from the earlier 2011 version in recognising ‘the established benefits of early initiation of DMARD treatment’. As a result, NSAIDs have been downgraded to adjunct therapy, ...
Already a member?
Enter your email to keep reading.